Peter Haubjerg Asdahl1,2, Rohit Priyadarshi Ojha3, Jeanette Falck Winther4, Anna Sällfors Holmqvist5, Sofie de Fine Licht4, Thorgerdur Gudmundsdottir4,6, Laura Madanat-Harjuoja7, Laufey Tryggvadottir8,9, Klaus Kaae Andersen4, Henrik Hasle10. 1. Department of Pediatrics, Aarhus University Hospital, Århus, Denmark. asdahl@rm.dk. 2. Department of Hematology, Hospital Unit Jutland West, Holstebro, Denmark. asdahl@rm.dk. 3. Center for Outcomes Research, JPS Health Network, Fort Worth, TX, USA. 4. Danish Cancer Society Research Center, Copenhagen, Denmark. 5. Pediatric Hematology and Oncology, Skåne University Hospital, Lund, Sweden. 6. Children's Hospital, Landspitali University Hospital, Reykjavík, Iceland. 7. Finnish Cancer Registry, Helsinki, Finland. 8. Faculty of Medicine, University of Iceland, Reykjavík, Iceland. 9. Icelandic Cancer Registry, Reykjavík, Iceland. 10. Department of Pediatrics, Aarhus University Hospital, Århus, Denmark.
Abstract
INTRODUCTION: Given considerable focus on health outcomes among childhood cancer survivors, we aimed to explore whether survivor bias is apparent during long-term follow-up of childhood cancer survivors. METHODS: We identified all 1-year survivors of cancer diagnosed before 20 years of age in Denmark, Finland, Iceland, and Sweden. From the general population, we randomly sampled a comparison cohort. Study individuals were followed for hospitalizations for diseases of the gastroenterological tract, endocrine system, cardiovascular system, or urinary tract from the start of the cancer registries to 2010. We estimated cumulative incidence with death as competing risk and used threshold regression to compare the hazards of the diseases of interest at ages 20, 40, 60, and 75 years. RESULTS: Our study included 27,007 one-year survivors of childhood cancer and 165,620 individuals from the general population. The cumulative incidence of all four outcomes was higher for childhood cancer survivors during early adulthood, but for three outcomes, the cumulative incidence was higher for the general population after age 55 years. The hazard ratios (HRs) decreased for all outcomes with increasing age, and for two of the outcomes, the hazards were higher for the general population at older ages (endocrine diseases: age-specific HRs = 3.0, 1.4, 1.0, 0.87; Cardiovascular diseases: age-specific HRs = 4.1, 1.4, 0.97, 0.84). CONCLUSIONS: Our findings provide empirical evidence that survivor bias attenuates measures of association when comparing survivors with the general population. The design and analysis of studies among childhood cancer survivors, particularly as this population attains older ages, should account for survivor bias to avoid misinterpreting estimates of disease burden.
INTRODUCTION: Given considerable focus on health outcomes among childhood cancer survivors, we aimed to explore whether survivor bias is apparent during long-term follow-up of childhood cancer survivors. METHODS: We identified all 1-year survivors of cancer diagnosed before 20 years of age in Denmark, Finland, Iceland, and Sweden. From the general population, we randomly sampled a comparison cohort. Study individuals were followed for hospitalizations for diseases of the gastroenterological tract, endocrine system, cardiovascular system, or urinary tract from the start of the cancer registries to 2010. We estimated cumulative incidence with death as competing risk and used threshold regression to compare the hazards of the diseases of interest at ages 20, 40, 60, and 75 years. RESULTS: Our study included 27,007 one-year survivors of childhood cancer and 165,620 individuals from the general population. The cumulative incidence of all four outcomes was higher for childhood cancer survivors during early adulthood, but for three outcomes, the cumulative incidence was higher for the general population after age 55 years. The hazard ratios (HRs) decreased for all outcomes with increasing age, and for two of the outcomes, the hazards were higher for the general population at older ages (endocrine diseases: age-specific HRs = 3.0, 1.4, 1.0, 0.87; Cardiovascular diseases: age-specific HRs = 4.1, 1.4, 0.97, 0.84). CONCLUSIONS: Our findings provide empirical evidence that survivor bias attenuates measures of association when comparing survivors with the general population. The design and analysis of studies among childhood cancer survivors, particularly as this population attains older ages, should account for survivor bias to avoid misinterpreting estimates of disease burden.
Entities:
Keywords:
Cancer survivorship; Childhood cancer; Competing risk; Healthy survivor effect; Late effects; Survivor bias
Authors: Raoul C Reulen; Aliki J Taylor; David L Winter; Charles A Stiller; Clare Frobisher; Emma R Lancashire; Fabienne M McClanahan; Elaine M Sugden; Mike M Hawkins Journal: Int J Cancer Date: 2008-11-01 Impact factor: 7.396
Authors: M C Corti; J M Guralnik; L Ferrucci; G Izmirlian; S G Leveille; M Pahor; H J Cohen; C Pieper; R J Havlik Journal: Am J Public Health Date: 1999-03 Impact factor: 9.308
Authors: Peter H Asdahl; Jeanette F Winther; Trine G Bonnesen; Sofie De Fine Licht; Thorgerdur Gudmundsdottir; Harald Anderson; Laura Madanat-Harjuoja; Laufey Tryggvadottir; Milada Cvancarova Småstuen; Anna Sällfors Holmqvist; Henrik Hasle; Jørgen H Olsen Journal: Pediatr Blood Cancer Date: 2015-07-20 Impact factor: 3.167
Authors: Thorgerdur Gudmundsdottir; Jeanette F Winther; Sofie de Fine Licht; Trine G Bonnesen; Peter H Asdahl; Laufey Tryggvadottir; Harald Anderson; Finn Wesenberg; Nea Malila; Henrik Hasle; Jørgen H Olsen Journal: Int J Cancer Date: 2015-03-14 Impact factor: 7.396
Authors: Jonas F Ludvigsson; Eva Andersson; Anders Ekbom; Maria Feychting; Jeong-Lim Kim; Christina Reuterwall; Mona Heurgren; Petra Otterblad Olausson Journal: BMC Public Health Date: 2011-06-09 Impact factor: 3.295
Authors: Jennifer Weuve; Cécile Proust-Lima; Melinda C Power; Alden L Gross; Scott M Hofer; Rodolphe Thiébaut; Geneviève Chêne; M Maria Glymour; Carole Dufouil Journal: Alzheimers Dement Date: 2015-09 Impact factor: 21.566
Authors: Nickhill Bhakta; Qi Liu; Frederick Yeo; Malek Baassiri; Matthew J Ehrhardt; Deo K Srivastava; Monika L Metzger; Matthew J Krasin; Kirsten K Ness; Melissa M Hudson; Yutaka Yasui; Leslie L Robison Journal: Lancet Oncol Date: 2016-07-25 Impact factor: 41.316